miRNA Regulation of the FGF23-Klotho Pathway Mitigates Adverse Cardiac Remodeling During Nocturnal Hemodialysis
BACKGROUND: Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in patients with ESKD. Dysregulation of the fibroblast growth factor 23 (FGF23)/Klotho axis has been implicated in uremic cardiomyopathy, however the mechanism linking dialysis intensity to the regulation of this pathway remains poorly defined. METHODS: We analyzed serum samples from ESKD patients transitioning from conventional to nocturnal hemodialysis (NHD). Left ventricular mass (LVM) was measured by echocardiography before and after transition. Patients were stratified as LVM regressors [ ≥ 10% decrease in LVM; n = 6] or LVM progressors [ ≥ 10% increase in LVM; n = 7]. Circulating microRNAs (miRs) and serum FGF23 and alpha Klotho were quantified. Mechanistic relevance was tested in an angiotensin-II model of cardiac hypertrophy using FGF23 suppression via an antisense oligonucleotide gapmer, or antagomirs targeting miR-200c-3p. RESULTS: Among 13 patients transitioning to NHD, LVM regressors required fewer antihypertensive medications than at baseline (P<0.001) with improved metabolic parameters (urea 12.9 vs. 16.6 mmol/L, P<0.01) and higher hemoglobin (109 vs. 95 g/L, P<0.01). We identified six differentially expressed miRs (let-7a/g/i, miR-200c, miR-1 and miR-30c) that targeted the FGF23/Klotho signaling axis. LVM regressors also demonstrated significantly lower circulating FGF23 levels than LVM progressors [60 (28, 160) vs 668 (73, 1734) pg/mL, P<0.05]. In the angiotensin-II murine model of cardiac hypertrophy, FGF23 gapmer treatment or miR-200c-3p inhibition reduced cardiomyocyte hypertrophy and attenuated interstitial fibrosis while restoring FGF23/Klotho signaling through the suppression of extracellular signal-regulated kinase 1/2 phosphorylation, activation of dual specificity phosphatase-1 and inducing antioxidant gene expression. CONCLUSIONS: Collectively, these exploratory findings link dialysis intensification to miR-mediated regulation of the FGF23/Klotho axis, demonstrating that targeting this regulatory network is sufficient to suppress pathological cardiac remodeling. These data provide a mechanistic basis for the cardiovascular benefits of nocturnal hemodialysis and identify the FGF23/Klotho axis as a candidate therapeutic target warranting further validation.
Authors
- Daniela Grothe
- Ludger Hauck
- Christopher T. Chan (ORCID: https://orcid.org/0000-0002-0947-7273)
- Filio Billia (ORCID: https://orcid.org/0000-0002-2824-1215)
- Benny Premsingh
- Carmine A Alberga (ORCID: https://orcid.org/0009-0008-1431-8198)
Institutions
- University Health Network (CA)
- Toronto General Hospital (CA)
- Ted Rogers Centre for Heart Research (CA)
- Toronto General Hospital Research Institute (CA)
Publication Details
- Journal
- Clinical Journal of the American Society of Nephrology
- Published
- 2026-11-19
- DOI
- https://doi.org/10.2215/cjn.0000001264
- Primary Topic
- Parathyroid Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00